Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26965308 | 1.00 | MGLL (0.45) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL13007049 | 0.99 | MGLL (0.42) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL28722860 | 0.91 | MGLL (0.46) | MGLLSMN1; SMN2HPGDHTTPTGS1 | |
| SCHEMBL29869052 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29869032 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL24621693 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL10018583 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL30259429 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29608026 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 | |
| SCHEMBL29441383 | 0.90 | MGLL (0.55) | MGLLCA2CA12CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747021-B1 | SELF-IMMOLATIVE LINKERS AND DRUG CONJUGATES | SQUIBB & SONS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399403-B2 | drug-ligand conjugates that are potent cytotoxins; stabilized therapeutic agents and markers; exhibit high specificity of action, reduced toxicity, and improved stability in blood ; antitumors | MEDAREX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2007038658-A2 | ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MEDAREX, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | MGLL 4151/4885CA2 4004/4885CA12 421/4885 |
| US-20100092496-A1 | CHEMICAL LINKERS AND CONJUGATES THEREOF | CLSPN, CD74, ANTXR2 | MGLL 4091/4885CA2 4082/4885CA12 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.